CJC-1295 (DAC)
CJC-1295 DAC is a long-acting research peptide designed to imitate growth hormone-releasing hormone. Researchers have studied how it influences growth hormone, IGF-1, and the natural signaling between the brain and pituitary gland.
CJC-1295 DAC AT A GLANCE
WHAT IS CJC-1295 DAC?
CJC-1295 DAC is a laboratory-designed version of growth hormone-releasing hormone, often shortened to GHRH. Natural GHRH is produced in the brain and signals the pituitary gland to release growth hormone.
The peptide includes a modification called a Drug Affinity Complex, or DAC. This modification helps it attach to albumin, a common protein in the blood, allowing CJC-1295 DAC to remain active much longer than natural GHRH.
HOW DOES CJC-1295 DAC WORK?
CJC-1295 DAC interacts with GHRH receptors on the pituitary gland. This encourages the pituitary to release growth hormone, which can then influence the production of insulin-like growth factor 1, commonly called IGF-1.
Its albumin-binding design protects the peptide from being cleared quickly. Human research estimated its half-life at approximately six to eight days, allowing researchers to examine longer-lasting hormone activity following a single administration.
Areas of Research
CJC-1295 DAC research focuses on the relationship between GHRH, the pituitary gland, growth hormone, and IGF-1. Studies have also examined how its extended activity changes the timing of these signals.
GROWTH HORMONE RELEASE
Studying how the peptide influences the amount and timing of growth hormone released by the pituitary gland.
IGF-1 SIGNALING
Examining changes in IGF-1, a hormone involved in growth, metabolism, and tissue activity.
PITUITARY FUNCTION
Exploring how the pituitary responds to a long-acting version of a naturally occurring hormone signal.
EXTENDED PEPTIDE ACTIVITY
Investigating how albumin binding allows the peptide to remain active for several days.
Research Highlights
In early studies involving healthy adults, a single administration of CJC-1295 produced sustained increases in growth hormone and IGF-1. Growth hormone remained elevated for several days, while changes in IGF-1 lasted even longer. Researchers also found that natural pulses of growth hormone continued during this extended activity.
These studies involved relatively few participants and were not designed to establish long-term safety or medical effectiveness. The FDA has since identified safety concerns and emphasizes that available clinical information remains limited.
WHAT IS CJC-1295 DAC MOST COMMONLY RESEARCHED FOR?
CJC-1295 DAC is most commonly studied for its prolonged influence on growth hormone and IGF-1. Researchers use it to examine how extending a GHRH-related signal affects pituitary activity and hormone patterns over several days. Early human research focused mainly on hormone measurements rather than proven health or performance outcomes.
HOW DOES CJC-1295 DAC FIT INTO PEPTIDE RESEARCH?
CJC-1295 DAC is part of peptide research involving hormones that coordinate communication between the brain, pituitary gland, and other tissues. It gives researchers a way to study GHRH-related activity over a longer period than natural GHRH ordinarily allows, helping them examine both hormone levels and patterns of release.
WHAT MAKES CJC-1295 DAC UNIQUE?
The DAC modification is what makes this peptide distinctive. It allows CJC-1295 DAC to attach to albumin and remain in circulation for several days. This creates a much longer-lasting signal than natural GHRH or shorter-acting GHRH-related peptides and is the primary difference between the DAC and No DAC versions.
CAN CJC-1295 DAC BE RESEARCHED ALONGSIDE OTHER PEPTIDES?
Researchers may compare CJC-1295 DAC with shorter-acting GHRH-related peptides such as sermorelin, tesamorelin, and CJC-1295 No DAC. It may also be examined alongside growth hormone secretagogues such as ipamorelin. These substances use different signaling pathways and should not be treated as interchangeable.
WHAT HAVE RESEARCHERS LEARNED ABOUT CJC-1295 DAC SO FAR?
Early human studies showed that CJC-1295 DAC can produce extended increases in growth hormone and IGF-1 while allowing growth hormone pulses to continue. Researchers also estimated a half-life of roughly six to eight days. However, these findings do not establish long-term safety, effectiveness, or benefits for muscle growth or healthy aging.
IS RESEARCH ON CJC-1295 DAC CONTINUING TODAY?
CJC-1295 DAC remains a research subject, but published human evidence is limited. The FDA has raised concerns involving immune reactions, peptide impurities, increased heart rate, and systemic blood-vessel reactions. More controlled research would be needed to understand its long-term activity and safety.